Focal Segmental Glomerulosclerosis (FSGS)
Nephrology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PfizerPF-06730512
Vertex PharmaceuticalsIXP
Vertex PharmaceuticalsVX-147
Clinical Trials (3)
Total enrollment: 104 patients across 3 trials
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Start: Oct 2018Est. completion: Feb 202347 patients
Phase 2Terminated
Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
Start: Aug 2024Est. completion: Dec 202436 patients
Phase 1Completed
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
Start: Jul 2023Est. completion: Sep 202321 patients
Phase 1Completed
Related Jobs in Nephrology
Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery
AstraZeneca
Sweden - Gothenburg
1w ago
Associate Director – Nephrology Market Access Strategy
Biogen
Cambridge, MA
1w ago
$164K - $226K/yr
Director, Strategy & Operations-Nephrology Franchise
Biogen
Cambridge, MA
1w ago
$195K - $269K/yr
Medical Science Liaison, CardioRenal - Portland, OR
AstraZeneca
Portland - OR, US
1w ago
Vice President, Head of Renal Sales
Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr
Specialty Account Manager, Nephrology- South Houston, Texas
Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space